Home/Filings/4/0001209191-20-042407
4//SEC Filing

Partridge Andrew John 4

Accession 0001209191-20-042407

CIK 0001595893other

Filed

Jul 13, 8:00 PM ET

Accepted

Jul 14, 5:40 PM ET

Size

7.4 KB

Accession

0001209191-20-042407

Insider Transaction Report

Form 4
Period: 2020-07-13
Partridge Andrew John
EVP & Chief Commercial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2020-07-13+127,500127,500 total
    Exercise: $59.94Exp: 2030-07-12Common Stock (127,500 underlying)
  • Award

    Common Stock

    2020-07-13+21,50021,500 total
Footnotes (2)
  • [F1]Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
  • [F2]25% of the shares vest on July 13, 2021 and 1/48th of the shares vest monthly thereafter over the next three years.

Issuer

Turning Point Therapeutics, Inc.

CIK 0001595893

Entity typeother

Related Parties

1
  • filerCIK 0001758838

Filing Metadata

Form type
4
Filed
Jul 13, 8:00 PM ET
Accepted
Jul 14, 5:40 PM ET
Size
7.4 KB